IBS-D

Last updated: November 1, 2023
Sponsor: CinPhloro Pharma, LLC
Overall Status: Active - Recruiting

Phase

2

Condition

Recurrent Diarrhea

Chronic Diarrhea

Irritable Bowel Syndrome (Ibs)

Treatment

N/A

Clinical Study ID

TX322038
CIN-103-121
  • Ages 18-90
  • All Genders

Study Summary

Treatment and relief of symptoms associated with irritable bowel syndrome (IBS) with predominant diarrhea (IBS-D).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Must be at least 18 years old male or female.
  • BMI between 18.0 and 40.0
  • Have IBS-D for at least 3 months.
  • Not have diagnosis of IBS-C
  • Not have history of abdominal surgery within the last 3 months before screening

Study Design

Study Start date:
Estimated Completion Date:

Study Description

A phase 2 randomized, Double-blind, Placebo-Controlled study 12 weeks in duration with 7 office visits and 1 follow-up visit after end of study.

Connect with a study center

  • Elite Clinical Studies, LLC

    Phoenix, Arizona 85018
    United States

    Active - Recruiting

    0.79 miles

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.